Cryo-Cell International, Inc. - 10-Q Summary
Business Context and Reporting Period
Cryo-Cell International, Inc. is engaged in the cellular processing and cryogenic storage of umbilical cord blood stem cells (U-Cord) and menstrual stem cells (C'elle). This report covers the quarterly period ended August 31, 2009, and the nine-month period ended on the same date. The company is classified as a smaller reporting company.
Key Financial Metrics
| Metric | Three Months Ended Aug 31, 2009 | Nine Months Ended Aug 31, 2009 |
|---|---|---|
| Revenue | $4,208,335 | $12,315,196 |
| Net Income | $434,724 | $1,702,358 |
| Operating Income | $514,313 | $1,770,320 |
| Cash and Cash Equivalents | $6,585,710 | $6,585,710 (Ending Balance) |
| Net Cash from Operating Activities | N/A | $3,217,000 |
| Cost of Sales Margin | 29% of Revenue | 29% of Revenue |
| Long-Term Debt | $0 | $0 |
Note: The company reported a net loss for the comparable periods in 2008.
Material Changes vs. Prior Period
- Revenue: Decreased 6% for both the three-month and nine-month periods compared to 2008. This was driven by an 8% decrease in specimens processed and a 24% increase in sales discounts, partially offset by an 11% increase in recurring storage fees.
- Profitability: The company returned to profitability, reporting net income of $1.7 million for the nine months ended August 31, 2009, compared to a net loss of $792,000 in the prior year period.
- Expenses:
- Cost of Sales: Decreased 25% (nine months) due to lower operational expenses and fewer specimens processed.
- Marketing, General & Administrative: Decreased 22% (nine months) due to reduced discretionary spending on advertising and personnel.
- R&D: Decreased 47% (nine months) as initial commercialization costs for the C'elle technology subsided.
- Liquidity: Cash and cash equivalents increased by approximately $3.0 million during the nine-month period, primarily due to strong operating cash flows.
Outlook, Risks, and Unusual Items
- Subsequent Event (Acquisition): On September 24, 2009, the company acquired assets and rights related to Safti-Cell, Inc., for $750,000 to assume a building lease and terminate a storage agreement. The first installment of $375,000 was paid immediately.
- Revenue Sharing Agreements (RSAs): Interest expense of $1.06 million (nine months) is primarily attributable to payments under RSAs, which require the company to share a percentage of future storage revenue with specific parties in exchange for upfront payments. This expense fluctuates with storage revenue volume.
- License Agreements: The company entered into a new license agreement with S-Evans Biosciences for mainland China and amended an agreement with LifeCell International to expand territory in India and surrounding regions.
- Risks: Key risks include increased government regulation of stem cell storage, market acceptance of new technologies (C'elle), competition, and the potential for increased warranty liabilities if engraftment failure rates rise.
- Warranty Reserves: The company maintains reserves of approximately $126,000 for product warranty and Cryo-Cell Cares programs, based on historical failure rates which have been very low.
Investor Verification Checklist
- Cash Runway: Verify that the $6.6 million cash balance is sufficient to fund the $750,000 Safti-Cell acquisition and anticipated $500,000 in capital expenditures over the next 12 months.
- Revenue Quality: Assess the sustainability of revenue given the 8% decline in specimens processed and the 24% increase in sales discounts.
- Warranty Liability: Monitor the assumptions used for the $126,000 warranty reserve, as a small increase in transplant failure rates could significantly impact this liability.
- International Exposure: Review the performance of international licensees (India, Venezuela, China) as they contribute significantly to licensee income and royalty revenue.
- Stock Compensation: Note that approximately $168,000 of unrecognized compensation cost remains for non-vested options, which will impact future earnings.